Four Houston accelerators will be working together this summer to advance nearly 30 university-associated startups. Photo via UH.edu

The University of Houston and Rice University have announced the cohorts for their summer accelerators that advance university-founded startups and small businesses.

The two schools run four programs in tandem with each other every summer for about a decade. There are nearly 30 companies this year being accelerated across the four programs, which are:

  • Rice's OwlSpark is focused on early-stage startup teams.
  • UH's RED Labs is focused on early-stage startup teams.
  • Rice's  BlueLaunch is focused on non-tech small businesses.
  • UH's RED Launch is focused on non-tech small businesses.

"A very cool part of the program is that we partner every summer with Rice University's OwlSpark and Blue Launch," says Liana Gonzalez-Schulenberg, managing director of RED Labs. "It creates this really incredible network across the universities and allows both schools to bolster and benefit from each other.

"We share staff, we share mentors, we share speakers, we co-host the demo day, and we even share the catering bill," she continues. "It's a really special part of the program that I think has brought endless value to the founders, the universities, and Houston."

The 12-week program takes each of the teams — all of which have a university-affiliated founder, from undergrad to faculty — through key programming and mentorship. The final event includes a pitch day, called the Bayou Startup Showcase, where all of the companies share their business plans they've created through the program.

“I’m excited to support these new ventures with highly curated offerings and rich mentorship, propelling them to commercial success,” said Jessica Fleenor, managing director of BlueLaunch and OwlSpark. "We have built a long-standing culture of advocacy and collaboration, and look forward to upholding that in our largest cohort to date."

The selected companies for the four programs are as follows.

RED Labs (cohort 11)

  • We Felt It 3-D prints customized modifications to mobility devices like canes, walkers, and wheelchairs that maximizes comfort during use.
  • Zoop makes nutrition easy, clean and sustainable smoothie premixes which can be consumed anywhere and anytime by just mixing it with any of the preferred mixer (Water, Vegan milk, Milk, etc.)
  • Orbit is an application that allows users to understand the stock market through practice and training.
  • Team X is creating a company around nanoporous membrane technologies that recovers metals from wastewater and brine.

OwlSpark (cohort 11)

  • Terradote will manufacture cost-competitive, petroleum-free chemicals using captured carbon dioxide, methane and renewable bio-based materials.
  • Biomethanator’s biofilm bioreactors utilize biomethanation to convert industrial-waste carbon dioxide to methane, which can be used as fuel or in other industrial applications.
  • Taurus Vascular is developing a minimally invasive catheter for addressing the most pressing complication of endovascular aortic aneurysm repair: endoleaks.
  • Voythos offers a mobile physician companion that monitors electronic medical records, prompting action and initiating care workflows.
  • AiKYNETIX is developing a video analytics platform for human motion insights, focusing on a mobile running lab for runners and coaches.
  • AllStars is building an affect-sensitive educational tool for self-studying and blended classroom learning.
  • Eureka Hub is developing a marketplace where data and research scientists can publish, manage, share and revise analytical models for data sets across diverse applications.
  • ScoutBetter is an end-to-end recruiting platform that connects students with corporate campuses and provides recruiters access to university talent.

RED Launch (cohort 2)

  • Curio Sweets is a vegan dessert brand that provides wholesale desserts and services including: consultation; recipe development; and contract baking of their product.
  • Space City Vinyl is a vehicle wrapping business that offers a quick and non permanent color change of vehicles.
  • Venus by Design is a handmade jewelry company
  • First Byte Digital consulting firm that helps mom and pop restaurants and non-profits establish a robust online presence by offering a wide range of digital conversion services.
  • 2tinys designs, prints, and cuts stickers with the plan of expanding into art prints and stationery items.
  • Lacey's Art paints dog portrait artwork. They partner with shelters to find models (and provide some help to getting the dog adopted), and then sells the prints.

BlueLaunch (cohort 2)

  • Archway Family Medicine provides medical care to patients through a monthly membership model known as direct primary care.
  • rdy helps communities recover from disasters faster and more equitably by working with local organizations to plan for them.
  • 610 Smokehouse is a mobile food service and catering company that serves “Texan Fusion,” a unique cuisine that combines traditional Texas barbecue with diverse Houston food.
  • Serendipity Picnic is a unique picnic with all the goodies and essentials wrapped in a beautiful, lightweight, easy-to-carry and reusable “BlanKIT.”
  • La Mer Macaron offers an assortment of homemade French macarons.
  • TenTwelve provides residential construction and remodeling services.
  • DHA America customizes, designs and sells powder-coated and galvanized fence panels, posts and accessories.
  • All About Baby provides bespoke tableware for babies transitioning to solid foods.
  • MeowPlanet is opening a cat lounge.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.